The national medical cannabis program has given Israel a head start in conducting research and developing products and processes around cannabis Israel’s pharmaceutical ecosystem, together with the Israeli government’s approval of medical cannabis research, facilitates cannabis research at universities and hospitals.
Israel is an approved and recognized site for clinical trials and has implemented Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) through the U.S.-Israel Science and Technology Commission (USISTC) Phytocannabinoids research for clinical trials is supported in Israel, as opposed to the USA where these are not approved and only synthetic ones are permitted.
BOL is positioned as a world leader in cannabinoid pharmaceutical drug development with a comprehensive cannabinoid clinical trial portfolio of 32 phase || randomized, double-blind, placebo-controlled trials
Israel is an approved and recognized site for clinical trials and has implemented Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) through the USA – Israel Science and Technology Commission (USISTC)
Expansion to new overseas markets and into new medical indications: BOL takes its product portfolio into clinical trials. This enables the penetration of global markets which require clinical trials as a prerequisite for commercialization, opens new medical indications and differentials our product portfolio.
Engages in collaborations with universities, academic and medical institutions to develop novel drugs and obtain regulatory approvals in a range of therapeutic areas
30+ clinical trials underway
Granted key patents for new innovative drug formulations and drug delivery systems
DRUG DELIVERY SYSTEM
BOL is developing a unique formulation and drug delivery system for the maintenance of active cannabinoids attributes, a combination of several active cannabinoids compounds designed to enhance bioavailability, increase efficacy and reduce side effects.
BOL uses a variety of administration methods
Oral: ora-mucosal spray, sublingual drops or tablets, and orally ingested capsules.
Trans-dermal: topical water-soluble solutions
Inhaled applications: vaporizers and metered dose inhalers
POSITIVE INITIAL FEEDBACK FROM AUTISM STUDY
“Every day something amazing happens. For instance, the writing phenomenon. Low functioning autistic children who do not speak usually stay within the refuge of their rooms; There is really no way to communicate with them. Suddenly, parents started reporting that their children are writing. When I saw what they wrote, I couldn’t believe it. Children whose behavioral issues were too severe to be allowed on a school bus, even with a caretaker, suddenly are sitting nicely in their seats.” Dr. Adi Aran